About sentinelone inc - S
S At a Glance
| Phone | 1-855-868-3733 | Revenue | 821.46M | |
| Industry | Packaged Software | Net Income | -288,441,000.00 | |
| Sector | Technology Services | 2025 Sales Growth | 32.248% | |
| Fiscal Year-end | 01 / 2026 | Employees | N/A | |
| View SEC Filings |
S Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 9.178 |
| Price to Book Ratio | 4.671 |
| Price to Cash Flow Ratio | 223.545 |
| Enterprise Value to EBITDA | -24.02 |
| Enterprise Value to Sales | 8.319 |
| Total Debt to Enterprise Value | 0.003 |
S Efficiency
| Revenue/Employee | 293,378.929 |
| Income Per Employee | -103,014.643 |
| Receivables Turnover | 3.481 |
| Total Asset Turnover | 0.347 |
S Liquidity
| Current Ratio | 1.638 |
| Quick Ratio | 1.638 |
| Cash Ratio | 1.182 |
S Profitability
| Gross Margin | 73.21 |
| Operating Margin | -40.094 |
| Pretax Margin | -34.281 |
| Net Margin | -35.113 |
| Return on Assets | -12.201 |
| Return on Equity | -17.678 |
| Return on Total Capital | -17.085 |
| Return on Invested Capital | N/A |
S Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 1.129 |
| Total Debt to Total Assets | 0.792 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 0.817 |
Sentinelone Inc in the News
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Several state officials demand feds protect Americans' retirement plans by clearly regulating ESG investments
"We request SEC and DoL take decisive action to uphold fiduciary duty laws," 22 state financial officers demanded in a letter to acting heads of both agencies.
One of Warren Buffett's favorite ETFs attracts $100B for first time
Investors are plowing money into the two largest ETFs that track the S&P 500, the broadest measure of the U.S. stock market. But each has different bragging rights.
The best ETFs for retirees
Americans are reaching retirement age at the fastest pace in U.S. history, and ETFs make it easier for investors to optimize their portfolios and gain exposure to specific sectors.
Media, Biden admin called out for 'amazing strategy' of claiming Americans don't understand economy
Journalist Matt Taibbi sounds off on the media and the White House "trying to tell people" that their perceptions of inflation and the economy are "irrational" or "partisan."
Running low on Ozempic or another weight loss drug? A new tracker can help
Telehealth company Ro has rolled out a new tool to track the supply of weight loss drugs like Ozempic and Wegovy across the U.S., as patients struggle with shortages.
Warren Buffett's favorite ETFs
While Warren Buffett is the largest investor in several of America's biggest companies, he also allocates some money into two ETFs that track the S&P 500, the broadest measure of U.S. stocks.
Nestlé launches food line targeting Ozempic, other weight-loss drug users
Nestlé's new food line, Vital Pursuit, is specifically targeted toward patients using weight-loss medications, which continues to surge in popularity.
Vanguard names BlackRock veteran as CEO: WSJ
Vanguard, the firm founded by John C. Bogle, may soon appoint the first outsider to be CEO in its 50-year history.
25K Americans starting Wegovy weekly as supply increases and prices drop, drugmaker says
Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week.